PHOSPHORYLATION OF HUMAN PLASMINOGEN ACTIVATORS AND PLASMINOGEN

被引:6
作者
BARLATI, S
DEPETRO, G
BONA, C
PARACINI, F
TONELLI, M
机构
[1] Division of Biology and Genetics, Department of Biomedical Sciences and Biotechnologies, University of Brescia, 25123 Brescia
关键词
HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; HUMAN PLASMINOGEN; PHOSPHORYLATION;
D O I
10.1016/0014-5793(95)00312-W
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasminogen (PG), urokinase-type plasminogen activator (u-PA) and tissue-type PA (t-PA) are the main molecules involved in fibrinolysis and in many other physiological and pathological processes. In the present study we report that human t-PA, purified from human melanoma cells, and PG, purified from human plasma, both contain P-Tyr residues, as revealed by immunoblotting analyses with monoclonal anti-P-Tyr antibodies. In addition HPLC amino acid analysis of acid-hydrolyzed t-PA, PG and u-PA, shows that: (i) P-Ser and P-Tyr residues are present in t-PA; (ii) P-Thr and P-Tyr are present in PG; (iii) P-Ser, P-Thr and P-Tyr are present in u-PA. The utilization of monoclonal anti-P-Ser and anti-P-Thr antibodies in immunoblotting experiments has confirmed these data which indicate that phosphorylation is a common feature of PAs and of PG.
引用
收藏
页码:170 / 174
页数:5
相关论文
共 50 条
[21]   Relationship between expression of plasminogen activator system and metastatic ability in human cancers [J].
NoguchiTakino, M ;
Endo, Y ;
Yonemura, Y ;
Sasaki, T .
INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (01) :97-105
[22]   Homology modeling of Mycoplasma pneumoniae enolase and its molecular interaction with human plasminogen [J].
Chumchua, Vasunun ;
Pornputtapong, Natapol ;
Thammarongtham, Chinae ;
Meksuriyen, Duangdeun .
BIOINFORMATION, 2008, 3 (01) :18-23
[23]   Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development [J].
Gonias, Steven L. ;
Zampieri, Carlotta .
CURRENT DRUG TARGETS, 2020, 21 (07) :647-656
[24]   Expression of urokinase type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer [J].
Kawasaki, K ;
Hayashi, Y ;
Wang, Y ;
Suzuki, S ;
Morita, Y ;
Nakamura, T ;
Narita, K ;
Doe, W ;
Itoh, H ;
Kuroda, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (09) :936-944
[25]   THE PLASMINOGEN-PLASMIN SYSTEM IN MALIGNANCY [J].
KWAAN, HC .
CANCER AND METASTASIS REVIEWS, 1992, 11 (3-4) :291-311
[26]   Urokinase-type plasminogen activator [J].
Crippa, Massimo P. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (04) :690-694
[27]   IMMUNOHISTOCHEMICAL LOCALIZATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INHIBITOR-2 IN EARLY HUMAN IMPLANTATION SITES [J].
HOFMANN, GE ;
GLATSTEIN, I ;
SCHATZ, F ;
HELLER, D ;
DELIGDISCH, L .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (02) :671-676
[28]   Angiostrongylus cantonensis:: Efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis [J].
Tu, Wu-Chun ;
Lai, Shih-Chan .
EXPERIMENTAL PARASITOLOGY, 2006, 113 (01) :8-15
[29]   Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression [J].
Liu, K ;
Liu, YX ;
Hu, ZY ;
Zou, RY ;
Chen, YJ ;
Mu, XM ;
Ny, T .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1997, 133 (02) :109-116
[30]   Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator [J].
Shenkman, Boris ;
Livnat, Tami ;
Budnik, Ivan ;
Tamarin, Ilia ;
Einav, Yulia ;
Martinowitz, Uriel .
BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (08) :729-733